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Key Points
It is necessary to include future non-breast cancer
costs in cost-effectiveness analyses.
Inclusion of future non-breast cancer costs does not
change our conclusions about the optimal treatment
strategy in Iran.
Dear Editor,
We welcome the comments on our article ‘‘Adjuvant
trastuzumab therapy for early HER2-positive breast cancer
in Iran: a cost-effectiveness and scenario analysis for an
optimal treatment strategy’’ [1] by Gershon and Berchenko
[2], who express the importance of including future non-
breast cancer costs in our cost-effectiveness analysis when
downstream costs1 are included in the analysis. As such,
they conclude that the optimal treatment regimen would be
1 year of trastuzumab use in the early stage with ‘‘only a
partial treatment in progressed stages’’. In this letter, we
respond to their commentary and discuss how much their
ideas can impact our results and conclusions.
In general, we agree with the opinion by Gershon and
Berchenko regarding the necessity of including future non-
breast cancer costs in cost-effectiveness analyses. Some
policy makers also believe that they should be included in
these analyses and have therefore included them in national
guidelines [3]. To explore the impact of future non-breast
cancer costs on the findings of our study, we first checked if
age-specific, future non-breast cancer costs are available in
Iran but, as far as we know, there is no reliable source for
these data. Therefore, we assumed that annual future non-
breast cancer costs are equal to the annual total health
expenditure per capita, which, when based on the per-
centage of the Iranian gross domestic product per capita
spent on healthcare multiplied by the gross domestic pro-
duct, is €497 (7.1% of €7000) [4]. We then updated the
results of our study using this value.
Figure 1 provides the results of the updated cost-effec-
tiveness analysis as well as our previous results [1]. As
Fig. 1 shows, the inclusion of future non-breast cancer
costs has very little effect on the results, although it does
lead to a slight reduction in the negative correlation
between incremental costs and incremental effectiveness
(i.e., the ‘clouds’ in Fig. 1b are not as slanted to the right as
those in Fig. 1a).
While some might expect that the relatively low costs
per year of €497 limit the effect of adding future non-breast
cancer costs on the results, this is just one of the factors that
play a role. Table 3 in our paper [1] shows that the life-
years gained from using trastuzumab is clinically important
but not large. For example, the base-case analysis results in
total life-years following 1 year of trastuzumab vs. no
trastuzumab of 15.82 vs. 14.41, which means a gain in life-
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years of 1.41. While women who received 1 year of tras-
tuzumab will incur extra costs because of a longer life, this
will amount to €701 (1.41 year *€497 per year); this
amount becomes smaller if we include discounting. Last, it
is worth pointing out that these costs are relatively small
compared with the cost of trastuzumab (€22,992), which is
incurred in the first year. This is the primary reason why
their inclusion has little impact on the cost-effectiveness
results.
Another point we would like to address is the suggestion
by Gershon and Berchenko that policy makers should
consider partial treatment of patients with advanced breast
cancer. While the idea of partial treatment might be
mathematically relevant, greater clarification is needed
about its definition and how it could be implemented in
routine practice. Possible interpretations of the term of
‘‘partial treatment’’ include less chemotherapy (doses or
frequency) per patient and treatment of only some patients
(e.g., using the principles of triage and stratified medicine).
Either way, clinicians would have to be willing to develop
a method for defining the term and designing a protocol
(preferably based on the literature and daily practice) to
implement this successfully.
In conclusion, we agree with the authors that it is nec-
essary to include future non-breast cancer costs in cost-
effectiveness analyses. However, their inclusion will not
always affect the results or the conclusions about the cost
effectiveness of one treatment strategy vs. another. The
magnitude of the impact of including the costs is deter-
mined by different factors, and their inclusion does not
change our conclusions about the optimal treatment strat-
egy of trastuzumab in Iran.
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Fig. 1 Cost-effectiveness planes showing the impact of including
non-breast cancer costs on the cost effectiveness of trastuzumab in
Iran; a shows the results when non-breast cancer costs are excluded
[1] while b shows the results when they are included. GDP gross
domestic product, QALYs quality-adjusted life-years
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